ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,633 | -22.7% | 158 | 0.0% | 0.00% | -25.0% |
| Q2 2023 | $7,289 | +15.0% | 158 | 0.0% | 0.00% | +33.3% |
| Q1 2023 | $6,336 | +92.6% | 158 | +122.5% | 0.00% | +50.0% |
| Q4 2022 | $3,289 | +9.6% | 71 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $3,000 | -25.0% | 71 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $4,000 | +33.3% | 71 | +91.9% | 0.00% | 0.0% |
| Q4 2021 | $3,000 | 0.0% | 37 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $3,000 | -25.0% | 37 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $4,000 | 0.0% | 37 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $4,000 | -33.3% | 37 | -22.9% | 0.00% | -50.0% |
| Q4 2020 | $6,000 | +50.0% | 48 | -43.5% | 0.00% | +33.3% |
| Q3 2019 | $4,000 | -33.3% | 85 | -9.6% | 0.00% | -25.0% |
| Q2 2019 | $6,000 | -14.3% | 94 | 0.0% | 0.00% | -20.0% |
| Q1 2019 | $7,000 | 0.0% | 94 | -3.1% | 0.01% | +66.7% |
| Q3 2018 | $7,000 | – | 97 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
| RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
| Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
| Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
| Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
| Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
| SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
| FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
| EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |